Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023
   Review
2. Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.European journal of clinical pharmacology · 2023
   Article
3. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.Internal and emergency medicine · 2023
   Article
4. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.Frontiers in pharmacology · 2023
   Article
5. Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
   Article
6. Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report.Cureus · 2022
   Article
7. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis.The Journal of infection · 2022
   Article
8. Bradyarrhythmia After Remdesivir Administration in SARS-CoV-2: A Review of Literature and Meta-Analysis of Observational Studies in Epidemiology.Cardiology research · 2022
   Article
9. Characteristics of bradyarrhythmia in patients with COVID-19: Systematic scoping review.Pacing and clinical electrophysiology : PACE · 2022
   Article
10. Post-COVID-19 maxillary osteonecrosis and floating maxillary teeth due to mucormycosis in two uncontrolled diabetic patients.Clinical case reports · 2022
    Article
11. Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.Frontiers in pharmacology · 2022
    Article
12. Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support.Qatar medical journal · 2022
    Article
13. Maxillary Mucormycotic Osteonecrosis as a Manifestation of Post-COVID-19 Infection in Non-diabetic Patients: Report of Two Cases.Journal of microscopy and ultrastructure
    Article
14. Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.International journal of critical illness and injury science
    Article

Corrections and comments

• Comment on
  Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia.2020

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as